Chonluten (T-34) (20mg)

What is the Chonluten (T-34) peptide?

Chonluten is also known as Tripeptide T-34. It is a cytogenetic complex consisting of short peptides which function primarily to normalize the mucous membrane cells of the lungs and the bronchial tube. It is a gene regulator associated with inflammation and antioxidant activity, and is involved in proliferation responses.^[1] It appears to function as an anti-inflammatory agent in the lungs, normalizing the mucosal functions of the lungs in conditions like asthma and chronic obstructive pulmonary disease (COPD). Clinical studies have suggested that Chonlunten may become essential in treating and preventing lung disorders, chronic respiratory infections, and bronchitis, and is effective in the maintaining the respiratory system of elderly patients.^[2] Chonluten studies report that the peptide is tolerable and thus far exhibits no side effects, complications, contraindications, or dependence associated with its use.

Specifications

Molecular Formula: C18H31N7O9

Molecular Weight: 318.27g/mol

Components: Peptide complex AC-7, microcrystalline cellulose, raw sugar, milk sugar (lactose), potato starch and twin-80

PubChem: CID 75007-24-8

Synonyms: T-34 tripeptide, EDG

Reconstitution: Required

Research

Chonluten and Bioregulation
Clinical studies have suggested that several peptides (di- and tri- peptides) play a role in slowing aging and increasing life span. These peptides are being actively reasearched for their potential to suppress oncogenes (genes that code for abnormal growth and spontaneous and induced tumors). These tripeptides may also play a role in regulating gene expression, including their role in cellular processes such as apoptosis. According to Dr. Khavinson, Chonluten and several other short peptides may bind to DNA and elicit their effects.^[3]

Chonluten and the Lungs
Clinical studies have been conducted, showing changes in tissue activity of the lungs and alterations in DNA expression in ways that normalize the mucosal tissue of the bronchi due to the apparent action of Chonluten.^[2] According to Avolio et al., peptides like Choluten “cooperate as natural inducers of TNF tolerance in monocyte, and act on macrophages as anti-inflammatory molecules during inflammatory and microbial-mediated activity.” Chonluten may be effective in treating and preventing bronchial function in acute and chronic respiratory diseases. Studies suggest that it may provide protection regardless of infectious or non-infectious etiology and may help maintain the respiratory system in both young and older adults. Chonluten in the lung appears to function to regulate genes such as the c-Fos, health shock protein gene HSP70, SOD, COX-2, TNF-alpha, and genes in the antioxidant system. The c-FOS protein is a potent regulator of cell proliferation, survival, and differentiation. This gene is most active in conditions like hypoxia and cellular destruction, and its effects are evident in the thickening of the mucosal wall of the bronchi. The potential for Chonluten to regulate c-FOS activity may improve positive pathophysiological changes in asthma cases and COPD. Experimental studies on Chonluten peptide therapy in patients with chronic bronchitis associated with an asthmatic component, appeared to contribute to a reduction in coughing and asthmatic attacks, and decreased the amount of sputum. These symptoms indicated an overall reduction in inflammatory and bronchospastic presentations of the disease.

Chonluten and the Gastrointestinal Tract (GIT)
It is important to note that research on the effects of Chonlunten in the GIT is still ongoing. So far, the actions of Chonluten in the GIT appear to be similar to those results witnessed in the lungs. Clinical studies have suggested that Chonluten may decrease the inflammatory and vascular changes seen in the GIT sequel to inflammatory diseases like Crohn’s disease and Ulcerative colitis.

Chonluten and Covid-19
During the covid-19 pandemic, peptides with very active anti-inflammatory effects were of interest to scientists. The peptides may prevent the evolution of pathological conditions during covid-19 by putting a halt to SARS-Co V-2 viral proteins, which would, in turn, have immuno- and bronchoprotective effects on the cells of the lungs. According to researchers, Chonluten has the potential to become a powerful peptide of interest in bronchopulmonary pathology.^[4] They suggest it may improve the effectiveness of standard therapy in chronic bronchitis with an asthmatic element, and has a stress-protective effect. In cases of low oxygen supply, Chonlunten appears to act to improve physiological functions and physical performance. This effect has suggested Chonluten to be a practical ancillary in the fight against covid-19.

Conclusion

Chonluten is a short peptide that appears to primarily normalize the mucosal cells of the lungs and bronchial tube. Its function doesn’t appear to be limited to the lungs and bronchial tubes. It may carry out secondary roles in the GIT, regulating genes involved in inflammatory and antioxidant activity and genes associated with proliferation responses to inflammation. Chonluten appears to carry out a regulatory function in the pulmonary mucosa. As a result, it may have applications in treating chronic inflammatory diseases of the lung such as asthma and COPD. Experimental studies report Chonluten appears to exhibit minimal side effects as seen in pregnancy, breastfeeding, and in individuals who are intolerant to it. In mice, it exhibits low oral and excellent subcutaneous bioavailability.

References